Table 1 In vitro infectivity to a hepatocyte line (HC-04) (potency) and sporozoite membrane integrity (viability) of the two lots of PfSPZ Challenge
A) Tübingen | ||
Release date | Potency ± standard deviation (No. of parasites expressing PfMSP-1/well) | Viability ± standard deviation |
Fresh* | 32.7 ± 1.5 parasites | 98.2% |
Release** | 29.3 ± 3.1 parasites | 87.4% ± 5.9% |
3 months | 27.3 ± 0.6 parasites | 84.6% ± 1.9% |
6 months | 26.7 ± 1.5 parasites | 83.6% ± 5.5% |
9 months | 26.3 ± 2.5 parasites | 86.3% ± 6.5% |
12 months | 27.3 ± 0.6 parasites | 86.2% ± 1.3% |
Post last clinical dose Tübingen | 24.0 ± 1.7 parasites | 81.7% ± 2.6% |
B) Barcelona | ||
Release date | Potency ± standard deviation (No. of parasites expressing PfMSP-1/well) | Viability ± standard deviation |
Fresh* | 28.3 ± 1.5 parasites | 95.5% |
Release** | 25.3 ± 1.5 parasites | 89% ± 2.2% |
3 months | 21.7 ± 1.5 parasites | 85% ± 3.3% |
6 months | 25.0 ± 5.3 parasites | 86% ± 4.8% |
Post last clinical dose Barcelona | 19.0 ± 1.0 parasites | 85% ± 4.4% |